SAFETY DATA SHEETS

This SDS packet was issued with item:

078952209

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078952190 078952191 078952192 078952193 078952202 078952206 078952208 078952210



SAFETY DATA SHEET

Zenrelia tablets

Section 1. Identification

GHS product identifier

: Zenrelia tablets

Product code

: 124000000847

Other means of identification

: ØA5536; CA5537; CA5538; CA5539; 3411067 Coated Tablets; 3411067 (Swift) (QA681N); Nem áll rendelkezésre.; Swift tablets; SWIFT 15MG TAB BULK TS; SWIFT 8.5MG TAB BULK TS; SWIFT 6.4MG TAB BULK TS; SWIFT 4.8MG TAB BULK TS; Zenrelia 15 mg; Zenrelia 8.5 mg; Zenrelia 6.4 mg; Zenrelia 4.8 mg; SWIFT TAB 4.8MG; SWIFT TAB 6.4MG; SWIFT TAB 8.5MG; SWIFT TAB 15MG; ZenreliaTM 15 mg Tablets for Dogs; ZenreliaTM 8.5 mg Tablets for Dogs; ZenreliaTM 4.8 mg Tablets for Dogs

Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Veterinary pharmaceutical.

Uses advised against: None known.

Company Name : Elanco US Inc.

2500 Innovation Way Greenfield IN, US 46140

Telephone number : 1-877 Elanco1 (1-877-352-6261)

Emergency telephone : Elanco Produ

number

Email

: Elanco Product Technical Support / Human or Animal Exposure Reporting:

1-888-545-5973

Transportation Emergency

: CHEMTREC: 1-800-424-9300

: elanco sds@elancoah.com

telephone number

(Outside U.S. CHEMTREC International: 00 1-703-527-3887)

Section 2. Hazards identification

OSHA/HCS status

: This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Classification of the substance or mixture

: FOXIC TO REPRODUCTION - Category 1B SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (bone marrow,

lymphatic system) - Category 2

GHS label elements

Hazard pictograms



Signal word : Danger

Hazard statements : H360 - May damage fertility or the unborn child.

H373 - May cause damage to organs through prolonged or repeated exposure. (bone

marrow, lymphatic system)

Precautionary statements

Prevention: P201 - Obtain special instructions before use.

P202 - Do not handle until all safety precautions have been read and understood. P280 - Wear protective gloves, protective clothing and eye or face protection.

P260 - Do not breathe dust.

Response : P308 + P313 - IF exposed or concerned: Get medical advice or attention.

Storage: P405 - Store locked up.

Product name: US : ENGLISH

Version : 0.09 Date of revision : 9 November 2023 Date of previous issue : 1 February 2023 1/10

Section 2. Hazards identification

Disposal

P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

Supplemental label

elements

: None known.

Hazards not otherwise

classified

: None known.

Section 3. Composition/information on ingredients

Substance/mixture

Ingredient name	%	CAS number
Munocitinib	≤3	1187594-14-4

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

Description of necessary first aid measures

Eye contact

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention following exposure or if feeling unwell.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact

: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. **Skin contact** : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact : No specific data.

Inhalation : Adverse symptoms may include the following:

> reduced fetal weight increase in fetal deaths skeletal malformations

Product name: Zenrelia tablets **US: ENGLISH** Version: 0.09 Date of revision: 9 November 2023 Date of previous issue: 1 February 2023 2/10

Section 4. First aid measures

Skin contact

Adverse symptoms may include the following:

reduced fetal weight increase in fetal deaths skeletal malformations

Ingestion

: Adverse symptoms may include the following:

reduced fetal weight increase in fetal deaths skeletal malformations

Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician

: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments

No specific treatment.

Protection of first-aiders

: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media

Suitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media

: None known.

Specific hazards arising from the chemical

: No specific fire or explosion hazard.

Hazardous thermal decomposition products

: Decomposition products may include the following materials: carbon dioxide carbon monoxide

nitrogen oxides phosphorus oxides metal oxide/oxides

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders: If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For nonemergency personnel".

Product name: Zenrelia tablets **US: ENGLISH** Version: 0.09 Date of revision: 9 November 2023 3/10 Date of previous issue: 1 February 2023

Section 6. Accidental release measures

Environmental precautions

Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill

: Move containers from spill area. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Dispose of via a licensed waste disposal contractor.

Large spill

: Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Dispose of via a licensed waste disposal contractor. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

Section 7. Handling and storage

Precautions for safe handling

Protective measures

: Put on appropriate personal protective equipment (see Section 8). Avoid exposure obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

Advice on general occupational hygiene

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

including any incompatibilities

Conditions for safe storage, : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
Minocitinib	None.

Biological exposure indices

No exposure indices known.

Appropriate engineering controls

: If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Product name: Zenrelia tablets **US: ENGLISH** Date of previous issue: 1 February 2023 4/10

Version: 0.09 Date of revision: 9 November 2023

Section 8. Exposure controls/personal protection

Hygiene measures

Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists. gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with sideshields.

Skin protection

Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

: Solid. [tablets] **Physical state**

Color Yellow.

Odor : Not available. Not available. **Odor threshold** pН : Not available. Melting point/freezing point : Not available. **Boiling point, initial boiling** : Not available. point, and boiling range

Flash point : Not applicable. **Evaporation rate** : Not available. : Not available. **Flammability** : Not applicable.

Lower and upper explosion limit/flammability limit

Vapor pressure : Not available. Relative vapor density : Not applicable.

Relative density Not available. Solubility(ies)

:	Media	Result
		Easily soluble Easily soluble

: Not available. Solubility in water

Product name: Zenrelia tablets **US: ENGLISH** Version: 0.09 Date of revision: 9 November 2023 Date of previous issue: 1 February 2023 5/10

Section 9. Physical and chemical properties and safety characteristics

Partition coefficient: n-

octanol/water

: Not applicable.

Auto-ignition temperature

Decomposition temperature

Not applicable.Not available.Not applicable.

Viscosity
Flow time (ISO 2431)

: Not available.

Particle characteristics

Median particle size

: Not available.

Section 10. Stability and reactivity

Reactivity: No specific test data related to reactivity available for this product or its ingredients.

Chemical stability: The product is stable.

Possibility of hazardous

reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

Conditions to avoid : No specific data.

Incompatible materials : No specific data.

Hazardous decomposition

products

: Under normal conditions of storage and use, hazardous decomposition products should

not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Not available.

Irritation/Corrosion

Not available.

Sensitization

Not available.

Mutagenicity

Not available.

Carcinogenicity

Not available.

Reproductive toxicity

Not available.

Teratogenicity

Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Product name :Zenrelia tabletsUS : ENGLISHVersion : 0.09Date of revision : 9 November 2023Date of previous issue : 1 February 20236/10

Section 11. Toxicological information

Name		Route of exposure	Target organs
Munocitinib	Category 2		bone marrow, lymphatic system

Aspiration hazard

Not available.

Information on the likely routes of exposure

: Not available.

Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 No known significant effects or critical hazards.
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.

Inhalation : Adverse symptoms may include the following:

reduced fetal weight increase in fetal deaths skeletal malformations

Skin contact: Adverse symptoms may include the following:

reduced fetal weight increase in fetal deaths skeletal malformations

Ingestion : Adverse symptoms may include the following:

reduced fetal weight increase in fetal deaths skeletal malformations

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Long term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

General: May cause damage to organs through prolonged or repeated exposure.

Carcinogenicity : No known significant effects or critical hazards.

Mutagenicity : No known significant effects or critical hazards.

Reproductive toxicity: May damage fertility or the unborn child.

Numerical measures of toxicity

Acute toxicity estimates

N/A

Product name :Zenrelia tabletsUS : ENGLISHVersion : 0.09Date of revision : 9 November 2023Date of previous issue : 1 February 20237/10

Section 12. Ecological information

Toxicity

Not available.

Persistence and degradability

Not available.

Bioaccumulative potential

Not available.

Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Other adverse effects

: No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods

: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains

Section 14. Transport information

	DOT Classification	TDG Classification	Mexico Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-	-	-
Transport hazard class(es)	-	-	-	-	-
Packing group	-	-	-	-	-
Environmental hazards	No.	No.	No.	No.	No.

Additional information

DOT Classification

: Reportable quantity 333.33 lbs / 151.33 kg. Package sizes shipped in quantities less than the product reportable quantity are not subject to the RQ (reportable quantity) transportation requirements.

Special precautions for user : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according : Not available.

to IMO instruments

Product name: Zenrelia tablets **US: ENGLISH** Version: 0.09 Date of revision: 9 November 2023 8/10 Date of previous issue: 1 February 2023

Section 15. Regulatory information

U.S. Federal regulations : TSCA 8(a) CDR Exempt/Partial exemption: Not determined

Clean Water Act (CWA) 311: acetic acid

Clean Air Act Section 112

(b) Hazardous Air **Pollutants (HAPs)** : Not listed

Clean Air Act Section 602

: Not listed

Class I Substances

Clean Air Act Section 602 Class II Substances

: Not listed

DEA List I Chemicals

: Not listed

(Precursor Chemicals)

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : TOXIC TO REPRODUCTION - Category 1B

SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (bone marrow,

lymphatic system) - Category 2

Composition/information on ingredients

Name	%	Classification
≶ tarch	≥10 - ≤25	COMBUSTIBLE DUSTS
ilunocitinib	≤3	COMBUSTIBLE DUSTS
		TOXIC TO REPRODUCTION - Category 1B
		SPECIFIC TARGET ORGAN TOXICITY (REPEATED
		EXPOSURE) (bone marrow, lymphatic system) - Category 2
magnesium distearate	≤3	COMBUSTIBLE DUSTS

State regulations

Massachusetts : The following components are listed: CELLULOSE; STARCH DUST

New York : None of the components are listed.

New Jersey : The following components are listed: CELLULOSE

Pennsylvania : The following components are listed: CELLULOSE; STARCH

California Prop. 65

⚠ WARNING: This product can expose you to Titanium dioxide, which is known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

Ingredient name	No significant risk level	Maximum acceptable dosage level
Tritanium dioxide	-	-

Inventory list

United States : Not determined.

Product name: zenrelia tablets **US: ENGLISH** Version: 0.09 Date of revision: 9 November 2023 9/10 Date of previous issue: 1 February 2023

Section 16. Other information

History

Date of issue/Date of

revision

: 11/9/2023

Date of previous issue : 2/1/2023 Version : 0.09

Key to abbreviations : ATE = Acute Toxicity Estimate

BCF = Bioconcentration Factor

GHS = Globally Harmonized System of Classification and Labelling of Chemicals

IATA = International Air Transport Association

IBC = Intermediate Bulk Container

IMDG = International Maritime Dangerous Goods

LogPow = logarithm of the octanol/water partition coefficient

MARPOL = International Convention for the Prevention of Pollution From Ships, 1973

as modified by the Protocol of 1978. ("Marpol" = marine pollution)

N/A = Not available SGG = Segregation Group UN = United Nations

References : Not available.

Indicates information that has changed from previously issued version.

Notice to reader

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:

Elanco Animal Health 0011+1-877-352-6261 0011+1-800-428-4441

Product name: US : ENGLISH

Version : 0.09 Date of revision : 9 November 2023 Date of previous issue : 1 February 2023 10/10